AIM Vaccine gets Chinese approval for a new influenza vaccine and an improved tetanus shot.

AIM Vaccine has received approval for a new influenza vaccine and an improved tetanus vaccine from China’s medical authorities. The influenza vaccine, made using MDCK cells, is the first of its kind approved in China and offers better safety and production quality than existing vaccines. AIM Vaccine also plans to develop a combined vaccine for multiple diseases, aiming to reduce the number of shots needed for children. These advancements could bring significant revenue growth and strengthen the company's position in the vaccine market.

3 months ago
4 Articles